enrasentan has been researched along with pd 156707 in 1 studies
| Studies (enrasentan) | Trials (enrasentan) | Recent Studies (post-2010) (enrasentan) | Studies (pd 156707) | Trials (pd 156707) | Recent Studies (post-2010) (pd 156707) |
|---|---|---|---|---|---|
| 32 | 2 | 0 | 11 | 0 | 4 |
| Protein | Taxonomy | enrasentan (IC50) | pd 156707 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.417 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0003 | |
| Endothelin receptor type B | Sus scrofa (pig) | 0.34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyd, SA; Chiou, WJ; Dixon, DB; Henry, KJ; Kozmina, NS; Liu, G; Marsh, KC; Nguyen, B; Opgenorth, TJ; Szczepankiewicz, BG; von Geldern, TW; Wasicak, J; Winn, M; Wu-Wong, JR | 1 |
1 other study(ies) available for enrasentan and pd 156707
| Article | Year |
|---|---|
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Topics: Administration, Oral; Animals; Atrasentan; Binding, Competitive; Biological Availability; CHO Cells; Cricetinae; Drug Design; Endothelin Receptor Antagonists; Humans; Kinetics; Male; Metabolic Clearance Rate; Molecular Conformation; Molecular Structure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Transfection | 1998 |